Restore Your Patients’ Confidence with SRT Therapy for Keloid Scars
The Issue with Keloid Scars
Keloid scars affect 18 million people, and many of them go through life believing that treatment for their embarrassing and sometimes painful scarring is impossible or even non-existent. Thick, unsightly keloid scars can significantly affect an individual’s confidence, but with the SRT-100™, you can help them gain it back.
Restore your patients’ confidence and self-esteem by offering post-surgical keloid treatment with Superficial Radiation Therapy (SRT therapy). Approved by the FDA for the treatment of keloid scars post-excision, the SRT-100™ by Sensus Healthcare has earned the moniker “The Keloid Cure.”
SRT therapy is a highly effective post-surgical keloid scar treatment with a long term cure rate of 86 percent.
How It Works
SRT therapy delivers a precise, calibrated dose of Superficial Radiation Therapy. This safely destroys the cells that form keloids, keeping the skin smooth as the incision heals. Furthermore, this painless keloid treatment can be performed in any physician’s office. But, patients may require a series of treatments, depending on the incision site.
Who Can Benefit
The SRT-100™ is ideal for patients that have recurring keloids. And, those who would like to find a solution to getting rid of their keloids for good. For the physician, the SRT-100™ offers many unique features including a broad range of motion; a compact, mobile design; precise and accurate x-ray delivery; variable applicator sizes; and replaceable contact shields.
Physicians, it is time to offer your patients another option: a painless and effective post-excision keloid scar treatment.
So, if you are a physician, contact Sensus Healthcare today to learn more about the SRT-100™ and the benefits it will bring to your practice.
Finally, if you are a patient and are interested in receiving treatment with SRT, contact Sensus Healthcare today to find where you can be treated by the SRT-100™.
**Originally posted on November 26, 2016. Updated on January 24, 2020.